WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
Wholly owned product candidates - advancing, with expanding news flow expected. Kadcyla ® sales growing - launches in European Union starting. Beyond Kadcyla - encouraging initial clinical findings now reported with six other compounds in development through partnerships.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be
Abstracts made public today provide insight on biological effects seen at low doses with IMGN529 and on observed activity threshold for IMGN853. Abstracts also add to growing body of data on the significance of partner compounds, including the findings reported on the activity and tolerability of
SAR3419 achieved objective responses well above the study threshold and was found to have a favorable safety profile. Objective responses reported in patients whose disease had not responded to prior therapy. Selected for Best of ASCO. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
Novel antibody-drug conjugate is designed to selectively target and kill CD33-expressing acute myeloid leukemia cells, including leukemic stem cells, while sparing normal cells. IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentation by Company management at an upcoming investor conference will be
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will participate in the Morgan Stanley Global Healthcare Conference .